Pulmonx (NASDAQ:LUNG) Announces Earnings Results

Pulmonx (NASDAQ:LUNG) issued its earnings results on Tuesday. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.07, FiscalAI reports. Pulmonx had a negative return on equity of 96.66% and a negative net margin of 55.03%. The firm had revenue of $22.84 million for the quarter, compared to the consensus estimate of $21.93 million.

Here are the key takeaways from Pulmonx’s conference call:

• Pulmonx returned to revenue growth in Q3 2026, with worldwide revenue up 6% year over year to $22.8 million; U.S. revenue rose 7% and international revenue increased 5%.
• Management reiterated full-year 2026 revenue guidance of $90 million to $92 million and expects growth to continue in Q4, supported by a rebuilt U.S. sales force and a refocused commercial strategy.
• Cost controls produced substantial operating leverage: adjusted EBITDA loss narrowed nearly 60% to $3.5 million, operating expenses fell 18%, and full-year cash burn is now expected to decline 30% to approximately $22 million.
• Gross margin improved to 76% in Q3, with full-year guidance raised to approximately 77%; management expects margins above 75% to support further leverage as revenue grows.
• China commercial activity is expected to resume by late 2026 or early 2027 following renewal of its registration certificate, but management emphasized that China represents only about 2% of expected business and may be lumpy; AeriSeal enrollment remains on track, with meaningful European revenue anticipated primarily from 2028.

Pulmonx Trading Up 9.6%

Shares of NASDAQ LUNG traded up $0.24 during midday trading on Thursday, hitting $2.76. The stock had a trading volume of 1,995,334 shares, compared to its average volume of 511,223. Pulmonx has a fifty-two week low of $1.13 and a fifty-two week high of $2.88. The firm has a market cap of $118.67 million, a P/E ratio of -2.39 and a beta of 0.33. The company has a debt-to-equity ratio of 0.95, a current ratio of 4.32 and a quick ratio of 3.52. The company’s 50-day simple moving average is $2.02 and its 200 day simple moving average is $1.65.

Insider Activity at Pulmonx

In other news, General Counsel David Lehman sold 14,334 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $2.26, for a total transaction of $32,394.84. Following the completion of the transaction, the general counsel directly owned 361,827 shares of the company’s stock, valued at $817,729.02. This trade represents a 3.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Srikanth Radhakrishnan sold 14,245 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total value of $32,193.70. Following the sale, the insider owned 316,994 shares in the company, valued at approximately $716,406.44. This represents a 4.30% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 78,340 shares of company stock worth $177,048. 7.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

LUNG has been the subject of a number of analyst reports. Canaccord Genuity Group set a $5.00 price target on Pulmonx in a research report on Wednesday. Weiss Ratings raised Pulmonx from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 25th. Finally, Stifel Nicolaus boosted their target price on Pulmonx from $2.50 to $4.00 and gave the stock a “buy” rating in a report on Wednesday. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.67.

About Pulmonx

Pulmonx Corporation is a medical device company focused on developing minimally invasive treatments for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company’s technologies are designed to reduce hyperinflation in damaged portions of the lung and help improve breathing, exercise capacity and quality of life.

Pulmonx’s primary product is the Zephyr Endobronchial Valve, a bronchoscopically implanted, one-way valve intended for certain patients with severe emphysema.